Clinical trials: Mucinous Adenocarcinoma
Gastrointestinal Neoplasms
Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei
Appendiceal cancer is a rare disease that does not cause many symptoms. As such, doctors are not sure if chemotherapy actually has an effect on the disease.
- Trial name
- NCT01946854
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Peritoneal Carcinomatosis
Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
Peritoneal carcinomatosis from advanced gastro-intestinal malignancy has historically been associated with poor overall survival (≤ 12 months) with few treatment options.
- Trial name
- NCT04779554
- Testing
- Mitomycin C, flat dose 40 mg, Mitomycin C, weight-based dose 12.5 mg/m2
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Prakash Pandalai
Pseudomyxoma Peritonei, Peritoneal Cancer
BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
Pseudomyxoma peritonei (PMP) is an orphan disease, characterized by the progressive accumulation of jelly-like material within the abdomen, which occurs in approximately 2-3 people per million per year.
- Conditions
- Pseudomyxoma Peritonei, Peritoneal Cancer, Mucinous Adenocarcinoma, Mucinous Tumor
- Trial name
- NCT03976973
- Testing
- Bromelain, Acetylcysteine, Interventional radiology insertion of drain
- Volunteers
- 62 people
- Sponsor
- Mucpharm Pty Ltd
Solid Tumor, Gastric Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04683939
- Testing
- BNT141, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- BioNTech SE
Pseudomyxoma Peritonei, Colorectal Carcinoma
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through…
- Conditions
- Pseudomyxoma Peritonei, Colorectal Carcinoma, Ovarian Carcinoma, Mesothelioma
- Trial name
- PSM (NCT02073500)
- Testing
- Observational study.
- Where
- Norway
- Volunteers
- 300 people
- Sponsor
- Oslo University Hospital
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms
A Study of SGN-STNV in Advanced Solid Tumors
This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms
- Trial name
- NCT04665921
- Testing
- SGN-STNV
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 111 people
- Sponsor
- Seagen Inc.
Pseudomyxoma Peritonei, Postoperative Delirium (POD)
Proactive Temperature Management in CRS-HIPEC for Prevention of Delirium
This randomized controlled trial evaluates the efficacy of a proactive Goal-Directed Temperature Management (GDTM) protocol in reducing postoperative delirium among patients undergoing Cytoreductive Surgery (CRS) with…
- Trial name
- NCT07378371
- Testing
- Proactive Goal-Directed Temperature Management, Standard Reactive Temperature Management
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Aerospace Center Hospital
Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
Phase I trial to study the effectiveness of paclitaxel, cisplatin, and topotecan with or without filgrastim in treating patients who have newly diagnosed stage III or stage IV epithelial ovarian cancer.
- Conditions
- Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma
- Trial name
- NCT00002913
- Testing
- paclitaxel, cisplatin, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
Pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge with 5-year survival rates of 13%, primarily attributable to advanced-stage diagnosis (AJCC Stage III/IV in >80% of cases).
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraepithelial Neoplasias, Intraductal Papillary Mucinous Neoplasm
- Trial name
- AI-PANC (NCT06638866)
- Testing
- PDAC, Pancreatic precursor lesions
- Where
- 3 sites in China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Colorectal Cancer Metastatic, Cancer Metastatic to the Peritoneal Cavity
Severe Neutropenia After HIPEC Using Mitomycin-C
Mitomycin-C (MMC) is the most commonly used chemotherapeutic agent for hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) to treat colorectal cancer patients with peritoneal metastases.
- Conditions
- Colorectal Cancer Metastatic, Cancer Metastatic to the Peritoneal Cavity, Appendiceal Neoplasm, Pseudomyxoma Peritonei
- Trial name
- NCT05513183
- Testing
- Intraoperative blood and peritoneal fluid samplings during HIPEC
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Gangnam Severance Hospital
Colorectal Cancer With a Resected Minimal Synchronous PC, Ovarian Metastases
Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients
Multicentric randomised trial. Patients with a high risk of developing colorectal Peritoneal Carcinomatosis (PC) after resection of their primary will be informed, will sign the consent and will be pre-registered.
- Conditions
- Colorectal Cancer With a Resected Minimal Synchronous PC, Ovarian Metastases, Tumour Rupture in the Abdominal Cavity
- Trial name
- ProphyloCHIP (NCT01226394)
- Testing
- laparotomy plus HIPEC
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial studies how well dalantercept works in treating patients with endometrial cancer that has come back or is persistent. Dalantercept may stop the growth of endometrial cancer by blocking blood flow to the tumor.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Mucinous Adenocarcinoma
- Trial name
- NCT01642082
- Testing
- Dalantercept, Laboratory Biomarker Analysis
- Where
- 30 sites in United States
- Volunteers
- 28 people
- Sponsor
- Gynecologic Oncology Group
Brenner Tumor, Malignant Ascites
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy works in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02122185
- Testing
- metformin hydrochloride, Chemotherapy
- Where
- 10 sites in United States
- Volunteers
- 111 people
- Sponsor
- University of Chicago
Mucinous Gastrointestinal Adenocarcinoma
A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces
This is a Phase II open-label trial evaluating the efficacy, and safety of Erbitux in patients with mucinous gastrointestinal adenocarcinoma involving the peritoneal surface.
- Trial name
- NCT00162110
- Testing
- cetuximab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Endometrial Cancer
Papillary Serous Carcinoma of the Endometrium
Primary Objectives: To evaluate the results of Paclitaxel and pelvic radiation in pelvic confined papillary serous carcinoma of the endometrium for both local control and overall survival.
- Trial name
- NCT00515073
- Testing
- Paclitaxel, Pelvic Radiation, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Appendiceal Adenocarcinoma, Colorectal
A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma
To learn if circulating tumor DNA (ctDNA) testing before cytoreductive surgery (CRS) with or without heated intraperitoneal chemotherapy (HIPEC) can show if patients have a low or high risk of the disease returning and help…
- Trial name
- NCT05947838
- Testing
- Circulating tumoral DNA directed neoadjuvant therapy arm
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments.
- Conditions
- Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum, Pseudomyxoma Peritonei
- Trial name
- TRANSCAPE (NCT06084780)
- Testing
- Intestinal, Multivisceral or Modified Multivisceral Transplantation, Alemtuzumab, Tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer
RATIONALE: Radiation therapy may kill any tumor cells remaining after surgery. PURPOSE: Phase I/II trial to study the effectiveness of brachytherapy in treating women who have stage I or stage II breast cancer.
- Trial name
- NCT00002873
- Testing
- brachytherapy
- Where
- 232 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Appendix Cancer, Pseudomyxoma Peritonei
The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry
ACPMP's first-ever patient-powered global patient registry/natural history study collects patient and caregiver information and data to fuel clinical trials and drive breakthroughs for appendix cancer and PMP.
- Trial name
- NCT07769346
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Appendix Cancer Pseudomyxoma Peritonei Research Foundation